{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Kumawat AK"],"pubmed_abstract":["The balance between pro- and anti-inflammatory cytokines released by immune and non-immune cells plays a decisive role in the progression of atherosclerosis. Interleukin (IL)-17A has been shown to accelerate atherosclerosis. In this study, we investigated the effect on pro-inflammatory mediators and atherosclerosis development of an Affibody molecule that targets IL17A. Affibody molecule neutralizing IL17A, or sham were administered <i>in vitro</i> to human aortic smooth muscle cells (HAoSMCs) and murine NIH/3T3 fibroblasts and <i>in vivo</i> to atherosclerosis-prone, hyperlipidaemic ApoE<sup>-/-</sup> mice. Levels of mediators of inflammation and development of atherosclerosis were compared between treatments. Exposure of human smooth muscle cells and murine NIH/3T3 fibroblasts <i>in vitr"],"journal":["Frontiers in cardiovascular medicine"],"pagination":["831039"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8907570"],"repository":["biostudies-literature"],"pubmed_title":["Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice."],"pmcid":["PMC8907570"],"pubmed_authors":["Soderstrom LA","Caravaca AS","Sirsjo A","Baumgartner R","Gistera A","Ketelhuth DFJ","Hellberg S","Zegeye MM","Jin H","Ljungberg LU","Frejd FY","Amegavie O","Kumawat AK","Gudmundsdotter L","Olofsson PS","Paramel GV"],"additional_accession":[]},"is_claimable":false,"name":"Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice.","description":"The balance between pro- and anti-inflammatory cytokines released by immune and non-immune cells plays a decisive role in the progression of atherosclerosis. Interleukin (IL)-17A has been shown to accelerate atherosclerosis. In this study, we investigated the effect on pro-inflammatory mediators and atherosclerosis development of an Affibody molecule that targets IL17A. Affibody molecule neutralizing IL17A, or sham were administered <i>in vitro</i> to human aortic smooth muscle cells (HAoSMCs) and murine NIH/3T3 fibroblasts and <i>in vivo</i> to atherosclerosis-prone, hyperlipidaemic ApoE<sup>-/-</sup> mice. Levels of mediators of inflammation and development of atherosclerosis were compared between treatments. Exposure of human smooth muscle cells and murine NIH/3T3 fibroblasts <i>in vitr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-25T23:02:08.987Z","creation":"2025-04-06T09:13:56.031Z"},"accession":"S-EPMC8907570","cross_references":{"pubmed":["35282365"],"doi":["10.3389/fcvm.2022.831039"]}}